Allergan, Inc. [SEP] dissolved or abolished
Botox Completion of the deal would increase its market capitalization to $147 billion. On March 17, 2015, Actavis, plc completed the acquisition of Allergan, Inc. in a cash and equity transaction valued at approximately $70.5 billion, and was folded into that company. The combination created a $23 billion diversified global pharmaceutical company with commercial reach across 100 countries. In June 2015, Actavis, plc officially changed its name to Allergan, plc.
In June Allergan, Inc. announced it would acquire Kythera Biopharmaceuticals for around $
1948 and pharmacist Gavin S. Herbert, who in 1950 established Allergan Pharmaceuticals, Inc. Allergan focused on the discovery and development of novel formulations for specialty markets, as well as intimate collaboration with physicians and the scientific community. 1953 saw Allergan producing eye drops and formulating new products such as the first cortisone eye drop to treat allergic inflammation and the first ophthalmic steroid decongestant.
Acquisitions.
Allergan became a publicly traded company in 1970 and was acquired by SmithKline Beckman for $259 million in 1980. After generating $756 million in